CM
CLDI icon

Cohanzick Management’s Calidi Biotherapeutics CLDI Stock Holding History

Cohanzick Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-21
Closed -$25K – 383
2022
Q1 		$25K Buy
+21
New +$24.8K 0.01% 329

Other funds holding CLDI

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GL
Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Cohanzick Management's CLDI Position: Q2 2022 in Review

Cohanzick Management sold out of Calidi Biotherapeutics (CLDI) in Q2 2022, closing a stake of 21 shares — an estimated $25K sold.

Cohanzick Management first reported a position in CLDI in Q1 2022 and held it in 1 quarter. The position peaked at $25K in Q1 2022. 42 funds tracked by Wall St. Rank hold CLDI as of Q2 2022.

  • Cohanzick Management reported no remaining Calidi Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Cohanzick Management sold 21 Calidi Biotherapeutics shares in Q2 2022, an estimated $25K.
  • Cohanzick Management first reported a position in Calidi Biotherapeutics in Q1 2022 and held it in 1 quarter.
  • Cohanzick Management's Calidi Biotherapeutics position peaked at $25K in Q1 2022.
  • 42 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2022.

Based on Cohanzick Management's 13F filing for Q2 2022, filed 12 Aug 2022.